$RLAY
Relay Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021027601 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $952.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.47M $4.760M
YoY Change 414.08% 55.05%
% of Gross Profit
Research & Development $30.62M $21.70M
YoY Change 41.12% 62.67%
% of Gross Profit
Depreciation & Amortization $919.0K $859.0K
YoY Change 6.98% 28.21%
% of Gross Profit
Operating Expenses $43.36M $26.46M
YoY Change 63.87% 61.33%
Operating Profit -$42.41M -$26.46M
YoY Change 60.27%
Interest Expense $230.0K $1.570M
YoY Change -85.35% -31.14%
% of Operating Profit
Other Income/Expense, Net $221.0K $1.572M
YoY Change -85.94% -2720.0%
Pretax Income -$42.18M -$24.89M
YoY Change 69.47% 75.53%
Income Tax
% Of Pretax Income
Net Earnings -$42.18M -$24.89M
YoY Change 69.51% 75.48%
Net Earnings / Revenue -4431.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$467.6K -$286.5K
COMMON SHARES
Basic Shares Outstanding 90.40M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $726.1M $334.2M
YoY Change 117.27%
Cash & Equivalents $262.7M $70.34M
Short-Term Investments $463.4M $263.9M
Other Short-Term Assets $7.800M $4.500M
YoY Change 73.33%
Inventory
Prepaid Expenses
Receivables $8.600M
Other Receivables $0.00
Total Short-Term Assets $742.4M $338.7M
YoY Change 119.2%
LONG-TERM ASSETS
Property, Plant & Equipment $5.907M $30.70M
YoY Change -80.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $900.0K
YoY Change 0.0%
Total Long-Term Assets $28.91M $31.60M
YoY Change -8.51%
TOTAL ASSETS
Total Short-Term Assets $742.4M $338.7M
Total Long-Term Assets $28.91M $31.60M
Total Assets $771.3M $370.3M
YoY Change 108.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.593M $4.000M
YoY Change 39.83%
Accrued Expenses $8.867M $7.400M
YoY Change 19.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.08M $11.50M
YoY Change 39.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.50M $23.30M
YoY Change -3.43%
Total Long-Term Liabilities $22.50M $23.30M
YoY Change -3.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.08M $11.50M
Total Long-Term Liabilities $22.50M $23.30M
Total Liabilities $38.56M $34.80M
YoY Change 10.8%
SHAREHOLDERS EQUITY
Retained Earnings -$446.4M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $732.8M -$202.4M
YoY Change
Total Liabilities & Shareholders Equity $771.3M $370.3M
YoY Change 108.3%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$42.18M -$24.89M
YoY Change 69.51% 75.48%
Depreciation, Depletion And Amortization $919.0K $859.0K
YoY Change 6.98% 28.21%
Cash From Operating Activities $46.64M -$22.33M
YoY Change -308.83% 106.41%
INVESTING ACTIVITIES
Capital Expenditures $476.0K $1.020M
YoY Change -53.33% -132.48%
Acquisitions
YoY Change
Other Investing Activities -$233.2M $51.39M
YoY Change -553.69%
Cash From Investing Activities -$233.6M $50.37M
YoY Change -563.8% -1704.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.055M $351.0K
YoY Change 485.47%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.055M 351.0K
YoY Change 485.47% -93.05%
NET CHANGE
Cash From Operating Activities 46.64M -22.33M
Cash From Investing Activities -233.6M 50.37M
Cash From Financing Activities 2.055M 351.0K
Net Change In Cash -184.9M 28.39M
YoY Change -751.42% -418.61%
FREE CASH FLOW
Cash From Operating Activities $46.64M -$22.33M
Capital Expenditures $476.0K $1.020M
Free Cash Flow $46.16M -$23.35M
YoY Change -297.67% 204.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8606000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7753000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
742434000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5907000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22127000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
878000
CY2020Q4 us-gaap Other Assets
OtherAssets
22000
CY2021Q1 us-gaap Assets
Assets
771346000
CY2020Q4 us-gaap Assets
Assets
799829000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5593000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6351000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8867000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5760000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1623000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1521000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16083000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13632000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22477000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22901000
CY2020Q4 rlay Restricted Stock Liability
RestrictedStockLiability
3000
CY2021Q1 us-gaap Liabilities
Liabilities
38560000
CY2020Q4 us-gaap Liabilities
Liabilities
36536000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
90000
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
90000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1179096000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1167367000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
64000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-446412000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-404228000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
732786000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
763293000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
771346000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
799829000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q1 rlay Vesting Of Restricted Common Stock Value
VestingOfRestrictedCommonStockValue
98000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-153000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90428554
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89991324
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90428554
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89906835
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
952000
CY2021Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rlay:CollaborationRevenueMember
CY2020Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rlay:CollaborationRevenueMember
CY2021Q1 us-gaap Revenues
Revenues
952000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30622000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21700000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12735000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4758000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
43357000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
26458000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-42405000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26458000
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
226000
CY2020Q1 us-gaap Interest Income Other
InterestIncomeOther
1572000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
221000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1572000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-42184000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24886000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.99
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90197579
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4153791
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-52000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1069000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-52000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1069000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42236000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23817000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2055000
CY2021Q1 rlay Vesting Of Restricted Common Stock Value
VestingOfRestrictedCommonStockValue
3000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9671000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-52000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-180438000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
351000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1455000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
1069000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-202351000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9671000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1455000
CY2021Q1 us-gaap Depreciation
Depreciation
919000
CY2020Q1 us-gaap Depreciation
Depreciation
859000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
321000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1632000
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-261000
CY2021Q1 rlay Increase Decrease In Lease Assets And Liabilities Net
IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet
-130000
CY2020Q1 rlay Increase Decrease In Lease Assets And Liabilities Net
IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet
-105000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-811000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2338000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3060000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2531000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-75000000
CY2021Q1 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
952000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-22000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
46640000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22334000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
476000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1020000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
619320000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
55609000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
386175000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
107000000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-233621000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50371000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2055000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
351000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2055000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
351000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184926000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28388000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
448524000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42832000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263598000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71220000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000
CY2021Q1 rlay Reclassification Of Restricted Stock Liability To Additional Paid In Capital
ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital
3000
CY2020Q1 rlay Reclassification Of Restricted Stock Liability To Additional Paid In Capital
ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital
98000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70342000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
878000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under <font style="color:#000000;">Accounting Standards Codification Topic 606, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font>, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates.</p>
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
463343000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
52000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
463355000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
230351000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
230415000
CY2021Q1 rlay Common Stock Restriction Period
CommonStockRestrictionPeriod
P4Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
11252710
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8376080
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9671000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1455000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
134829000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M2D
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8886886
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
67727445

Files In Submission

Name View Source Status
0001564590-21-027601-index-headers.html Edgar Link pending
0001564590-21-027601-index.html Edgar Link pending
0001564590-21-027601.txt Edgar Link pending
0001564590-21-027601-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlay-10q_20210331.htm Edgar Link pending
rlay-20210331.xml Edgar Link completed
rlay-20210331.xsd Edgar Link pending
rlay-20210331_cal.xml Edgar Link unprocessable
rlay-20210331_def.xml Edgar Link unprocessable
rlay-20210331_lab.xml Edgar Link unprocessable
rlay-20210331_pre.xml Edgar Link unprocessable
rlay-ex102_187.htm Edgar Link pending
rlay-ex104_188.htm Edgar Link pending
rlay-ex311_6.htm Edgar Link pending
rlay-ex312_7.htm Edgar Link pending
rlay-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending